Please ensure Javascript is enabled for purposes of website accessibility

How DexCom's Q1 Results Trounced Wall Street Expectations

By Keith Speights - Apr 29, 2020 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The COVID-19 outbreak didn't dampen demand for the company's popular G6 CGM system.

It makes sense that the stocks of companies that have developed or are developing products to fight COVID-19 have skyrocketed in 2020. The same is true for stocks of companies that directly benefit from the shelter-at-home regulations that have been in force. But DexCom (DXCM -2.48%) doesn't belong in either category and has still seen its shares soar more than 50% year to date.

The maker of continuous glucose monitoring (CGM) systems announced its first-quarter results after the market closed on Tuesday. And it looks like DexCom's good times will keep on rolling. Investors appeared to be pleased with the company's results, with the healthcare stock jumping more than 6% in after-hours trading on Tuesday. Here are the highlights from DexCom's Q1 update.

Dexcom's glucose monitoring app on smart phone

Image source: DexCom.

By the numbers

DexCom announced first-quarter revenue of $405.1 million, an impressive 44% year-over-year jump. This result trounced the average analysts' Q1 revenue estimate of $357.6 million.

The company generated net income in the first quarter of $19.9 million, or $0.21 per share, based on generally accepted accounting principles (GAAP). This was a huge improvement from the prior-year period when DexCom posted a net loss of $26.9 million, or $0.30 per share.

Wall Street focuses more on adjusted non-GAAP earnings. DexCom didn't disappoint on that score, either, reporting Q1 adjusted earnings of $41.4 million, or $0.44 per share. This represented a stark contrast from the company's adjusted net loss of $4.6 million, or $0.05 per share, recorded in the same quarter of 2019. It also blew away the consensus analysts' adjusted earnings estimate of $0.14 per share.

Behind the numbers

DexCom CEO Kevin Sayer aptly summed up his company's strong Q1 performance by stating the continued momentum was "driven by growing awareness and customer satisfaction with our G6 CGM technology." The company attributed its revenue growth primarily to volume growth in sales of the G6 system.

There really weren't any negatives to be found in DexCom's Q1 results. Operating expenses climbed nearly 22% year over year to $222.9 million. However, that increase paled in comparison to the company's revenue growth.

DexCom did spend $3.2 million in incremental costs related to the COVID-19 outbreak. These were mainly related to additional spending on payroll, consulting, information technology infrastructure, and facilities. But the company was able to shrug off these extra costs with soaring demand for its G6 CGM continuing in spite of the pandemic. 

Looking ahead

The one significant impact that COVID-19 is having on DexCom is that the uncertainties related to the pandemic resulted in the company temporarily suspending its 2020 guidance. DexCom anticipates that it could experience some impact from patients staying at home and clinicians shifting to virtual care models. However, it also stated that it "has seen benefits in the shift to telemedicine" including increased appreciation for its virtual diabetes care offerings and monitoring of patients in hospitals.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom, Inc. Stock Quote
DexCom, Inc.
$74.70 (-2.48%) $-1.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.